Jan Marini responds to Latisse
This article was originally published in The Rose Sheet
Executive Summary
Marini Lash Eyelash Conditioner "is a safe and cost-effective alternative to the new prescription-based Latisse product by Allergan for consumers seeking dense, lush-looking lashes," according to Jan. 22 release from Jan Marini Skin Research, which provides a head-to-head comparison of the two products. For example, one year of Latisse (12 monthly applications at $120 apiece) costs roughly $1,440, while a year's supply of Marini Lash (two 0.23 oz., $160 tubes) costs $320. JMSR notes that neither Marini Lash nor its companion product, Marini Mascara Performance Mascara, contain bimatoprost - the active drug in Latisse that was used first in an Allergan glaucoma treatment - though an earlier-generation Marini eyelash enhancer did (1"The Rose Sheet" Dec. 15, 2008, p. 7). "With Marini Lash, anyone can have thicker and lusher-appearing lashes without the substantial cost or warning labels that accompany the Latisse prescription product," the company says, adding that it "is also fantastic for eyebrows." Allergan has launched a multi-pronged campaign to raise consumer awareness of Latisse, the only eyelash enhancer with FDA's stamp of approval (2"The Rose Sheet" Jan. 12, 2009, p. 3)